Literature DB >> 18021020

Antigen-specific tolerance of human alpha1-antitrypsin induced by helper-dependent adenovirus.

V Cerullo1, W McCormack, M Seiler, V Mane, R Cela, C Clarke, J R Rodgers, B Lee.   

Abstract

As efficient and less toxic virus-derived gene therapy vectors are developed, a pressing problem is to avoid immune response to the therapeutic gene product. Secreted therapeutic proteins potentially represent a special problem, as they are readily available to professional antigen-presenting cells throughout the body. Some studies suggest that immunity to serum proteins can be avoided in some mouse strains by using tissue-specific promoters. Here we show that expression of human alpha1-antitrypsin (AAT) was nonimmunogenic in the immune-responsive strain C3H/HeJ, when expressed from helper-dependent (HD) vectors using ubiquitous as well as tissue-specific promoters. Coadministration of less immunogenic HD vectors with an immunogenic first-generation vector failed to immunize, suggesting immune suppression rather than immune stealth. Indeed, mice primed with HD vectors were tolerant to immune challenge with hAAT emulsified in complete Freund's adjuvant. Such animals developed high-titer antibodies to coemulsified human serum albumin, showing that tolerance was antigen specific. AAT-specific T cell responses were depressed in tolerized animals, suggesting that tolerance affects both T and B cells. These results are consistent with models of high-dose tolerance of B cells and certain other suppressive mechanisms, and suggest that a high level of expression from HD vectors can be sufficient to induce specific immune tolerance to serum proteins.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18021020     DOI: 10.1089/hum.2006.036

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  11 in total

1.  Improved induction of immune tolerance to factor IX by hepatic AAV-8 gene transfer.

Authors:  Mario Cooper; Sushrusha Nayak; Brad E Hoffman; Cox Terhorst; Ou Cao; Roland W Herzog
Journal:  Hum Gene Ther       Date:  2009-07       Impact factor: 5.695

2.  Coaxing the liver into preventing autoimmune disease in the brain.

Authors:  Brad E Hoffman; Roland W Herzog
Journal:  J Clin Invest       Date:  2008-10       Impact factor: 14.808

3.  NOD2 signaling contributes to the innate immune response against helper-dependent adenovirus vectors independently of MyD88 in vivo.

Authors:  Masataka Suzuki; Racel Cela; Terry K Bertin; Gautam Sule; Vincenzo Cerullo; John R Rodgers; Brendan Lee
Journal:  Hum Gene Ther       Date:  2011-07-08       Impact factor: 5.695

Review 4.  Hepatic gene transfer as a means of tolerance induction to transgene products.

Authors:  Paul A LoDuca; Brad E Hoffman; Roland W Herzog
Journal:  Curr Gene Ther       Date:  2009-04       Impact factor: 4.391

5.  Differential type I interferon-dependent transgene silencing of helper-dependent adenoviral vs. adeno-associated viral vectors in vivo.

Authors:  Masataka Suzuki; Terry K Bertin; Geoffrey L Rogers; Racel G Cela; Irene Zolotukhin; Donna J Palmer; Philip Ng; Roland W Herzog; Brendan Lee
Journal:  Mol Ther       Date:  2013-01-15       Impact factor: 11.454

6.  Immunogenicity of Cas9 Protein.

Authors:  Aditi Mehta; Olivia M Merkel
Journal:  J Pharm Sci       Date:  2019-10-04       Impact factor: 3.534

Review 7.  Evading the immune response upon in vivo gene therapy with viral vectors.

Authors:  Brandon K Sack; Roland W Herzog
Journal:  Curr Opin Mol Ther       Date:  2009-10

8.  Helper-Dependent Adenoviral Vectors.

Authors:  Amanda Rosewell; Francesco Vetrini; Philip Ng
Journal:  J Genet Syndr Gene Ther       Date:  2011-10-29

9.  Induction of immune tolerance to FIX following muscular AAV gene transfer is AAV-dose/FIX-level dependent.

Authors:  Meagan E Kelly; Jiacai Zhuo; Arpita S Bharadwaj; Hengjun Chao
Journal:  Mol Ther       Date:  2009-02-24       Impact factor: 11.454

10.  Combinatorial treatment with oncolytic adenovirus and helper-dependent adenovirus augments adenoviral cancer gene therapy.

Authors:  Lisa Farzad; Vincenzo Cerullo; Shigeki Yagyu; Terry Bertin; Akseli Hemminki; Cliona Rooney; Brendan Lee; Masataka Suzuki
Journal:  Mol Ther Oncolytics       Date:  2014-12-17       Impact factor: 7.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.